(E/Z)-BML264

• Product Name Alternative:

  MK-0822

• UNSPSC Description:

  (E/Z)-BML264 (N-(p-amylcinnamoyl) Anthranilic Acid) is a broad spectrum Phospholipase A2 (PLA2) inhibitor and TRP channel blocker[1][2]. (E/Z)-BML264 (N-(p-amylcinnamoyl) Anthranilic Acid) is also an effective reversible inhibitor of calcium-activated chloride channels, has potential to treat arrhythmia[3].

• Target Antigen:

  Phospholipase; TRP Channel

• Type:

  Reference compound

• Related Pathways:

  Membrane Transporter/Ion Channel;Metabolic Enzyme/Protease;Neuronal Signaling

• Field of Research:

  Cardiovascular Disease

• Assay Protocol:

  https://www.medchemexpress.com/e-z-bml264.html

• Purity:

  99.63

• Solubility:

  DMSO : 233.33 mg/mL (ultrasonic)

• Smiles:

  CCCCCC1=CC=C(C=C1)/C=C/C(NC2=CC=CC=C2C(O)=O)=O

• Molecular Weight:

  337.41

• References & Citations:

  [1]Kraft R, et al. Inhibition of TRPM2 cation channels by N-(p-amylcinnamoyl)anthranilic acid. Br J Pharmacol. 2006 Jun;148(3):264-73.|[2]Harteneck C, et al. N-(p-amylcinnamoyl)anthranilic acid (ACA): a phospholipase A(2) inhibitor and TRP channel blocker. Cardiovasc Drug Rev. 2007 Spring;25(1):61-75.|[3]Gwanyanya A, et al. Inhibition of the calcium-activated chloride current in cardiac ventricular myocytes by N-(p-amylcinnamoyl)anthranilic acid (ACA). Biochem Biophys Res Commun. 2010 Nov 19;402(3):531-6.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  -20°C, 3 years; 4°C, 2 years (Powder)

• Clinical Information:

  No Development Reported

• CAS Number:

  110683-10-8